Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2B Study of Memantine for the Treatment of Amyotrophic Lateral Sclerosis

NCT02118727 is registered in ClinicalTrials.gov with University of Kansas Medical Center as lead sponsor.

NCT NCT02118727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02118727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2B Study of Memantine for the Treatment of Amyotrophic Lateral Sclerosis
Lead sponsor
University of Kansas Medical Center
Phase
Phase 2
Overall status
Completed
Start date
November 7, 2018
Completion date
July 22, 2021
Enrollment
89 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis, frontal temporal dementia